Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended June 30, 2007
Business Overview: BD is a medical technology company operating through three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2007 | Nine Months Ended June 30, 2007 |
|---|---|---|
| Revenues | $1,631,159,000 | $4,708,607,000 |
| Operating Income | $327,537,000 | $859,431,000 |
| Net Income | $244,809,000 | $630,221,000 |
| Diluted EPS (Continuing Ops) | $0.95 | $2.38 |
| Gross Profit Margin | 51.5% | 51.9% |
| Operating Cash Flow (9mo) | $874,907,000 | |
| Total Debt | $1,158,884,000 (Short-term: $205.8M; Long-term: $953.1M) | |
| Cash and Equivalents | $444,164,000 | |
| Debt-to-Capitalization | 20.7% |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 12% in the quarter and 10% for the nine-month period compared to the prior year, driven by volume increases of approximately 9% and favorable foreign currency translation of 3%.
- Profitability: Operating income rose 14% in the quarter and 1% for the nine-month period. Gross profit margins improved to 51.5% (quarter) and 51.9% (nine months) due to favorable product mix and productivity gains.
- Acquisition Charges: The nine-month results included $122.1 million in non-deductible charges for acquired in-process research and development (IPR&D) related to the TriPath and Plasso acquisitions. This reduced diluted EPS by $0.48 for the nine-month period.
- Discontinued Operations: The company sold its blood glucose monitoring (BGM) product line in December 2006. Results are now presented as discontinued operations, contributing a net income of $23.2 million for the nine months ended June 30, 2007.
- Segment Performance:
- Medical: Revenues up 10% (quarter) and 10% (nine months); Operating income up 17% (quarter).
- Diagnostics: Revenues up 15% (quarter) and 9% (nine months); Operating income down 20% for the nine months due to the $114.7 million TriPath IPR&D charge.
- Biosciences: Revenues up 13% (quarter) and 12% (nine months); Operating income up 12% (quarter) and 16% (nine months).
Guidance, Outlook, and Risks
- Outlook: Management expects gross profit margins to improve by approximately 70 basis points in 2007. Selling and administrative expenses are expected to increase by 40 basis points, and R&D expenses by 20% for the full year, largely due to TriPath integration.
- Tax Rate: The reported tax rate for 2007 is expected to be approximately 29%, impacted by non-deductible IPR&D charges.
- Capital Allocation: Capital spending for 2007 is expected to be in the $600 million range. The company repurchased $412 million of common stock in the first nine months of 2007 and authorized an additional 10 million share repurchase program in July 2007.
- Legal and Contingencies:
- Retractable Technologies: Lawsuit alleging patent infringement and antitrust violations; BD intends to vigorously defend.
- Antitrust Class Actions: Ten consolidated class action lawsuits pending; motions to dismiss were denied.
- Oil-for-Food Programme: French Judicial Police investigation ongoing regarding UN contracts; BD internal review found no evidence of improper payments.
- bioMérieux: Arbitration regarding GeneOhm sublicense settled with no material financial impact.
- Market Risks: Exposure to foreign currency fluctuations, raw material costs (specifically resins/oil prices), and potential product recalls or regulatory actions.
Investor Verification Checklist
- Verify the impact of the $122.1 million IPR&D charges on the Diagnostics segment's operating income and the company's effective tax rate.
- Confirm the status of the French Judicial Police investigation regarding the UN Oil-for-Food Programme and potential future accruals.
- Monitor the progress of the ten consolidated antitrust class action lawsuits and the Retractable Technologies patent litigation.
- Assess the integration progress and revenue contribution of the TriPath acquisition against the $115 million charge taken.
- Review the company's ability to maintain gross margin improvements amidst rising raw material costs (resins) and foreign currency volatility.